Global Needle Free Drug Delivery Market Outlook 2020
Needle free drug delivery technology is an innovative technique to deliver drugs into a person’s body without piercing their skin. The global needle free drug delivery industry has been riding the tidal waves for the past few years, growing swiftly and presenting ample opportunities to the industry’s players. With favorable demographics, positive eco-financial dynamics, and rising awareness, the global needle free drug delivery market is poised to scale newer acmes. Moreover, augmented M&A activity in the industry, introduction of novel needle free drug delivery devices like Micro needles patch and roller, and entry of new players, are set to further boost the market’s growth.
The latest research by RNCOS titled, “Global Needle Free Drug Delivery Market Outlook 2020”, unfolds the market dynamics of the needle free drug delivery market. In this report, the global needle free drug delivery industry has been split into five distinct segments viz.: Jet injectors, Transdermal Patches, Micro Needles, and Oral and Inhalation drug delivery, depicting their current and future outlook to 2020. The transdermal patches and inhalation drug delivery system markets are further divided into sub-segments, with each segment scrutinized in detail. The report identifies and highlights the segments that offer the maximum opportunity for growth in the global market.
Our industry analysts studied all the facets of the global needle free drug delivery market to portray a crystal clear picture of the current as well as the expected future market outlook. Major drivers and trends have been identified that will act as catalysts towards boosting the industry’s growth along with roadblocks hindering the market growth. The study also delves into the regulatory environment affecting the needle free drug delivery devices in a number of countries.
It further highlights the competitive landscape of the global needle free drug delivery market, describing the business, financials, Strengths and weaknesses and recent developments of major industry players. This will help the reader to gain crucial insight into the key market players’ performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global needle free drug delivery industry.
The latest research by RNCOS titled, “Global Needle Free Drug Delivery Market Outlook 2020”, unfolds the market dynamics of the needle free drug delivery market. In this report, the global needle free drug delivery industry has been split into five distinct segments viz.: Jet injectors, Transdermal Patches, Micro Needles, and Oral and Inhalation drug delivery, depicting their current and future outlook to 2020. The transdermal patches and inhalation drug delivery system markets are further divided into sub-segments, with each segment scrutinized in detail. The report identifies and highlights the segments that offer the maximum opportunity for growth in the global market.
Our industry analysts studied all the facets of the global needle free drug delivery market to portray a crystal clear picture of the current as well as the expected future market outlook. Major drivers and trends have been identified that will act as catalysts towards boosting the industry’s growth along with roadblocks hindering the market growth. The study also delves into the regulatory environment affecting the needle free drug delivery devices in a number of countries.
It further highlights the competitive landscape of the global needle free drug delivery market, describing the business, financials, Strengths and weaknesses and recent developments of major industry players. This will help the reader to gain crucial insight into the key market players’ performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global needle free drug delivery industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. DRIVERS
3.1 Increasing Incidence of Chronic Diseases
3.2 Increased Affordability
3.3 Benefits over Conventional Drug Delivery Devices
3.4 Expansion in Emerging Markets
4. CHALLENGES
4.1 High Prices
4.2 Testing and Regulatory Issues
4.3 Low Awareness
5. REGULATORY LANDSCAPE
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
6. NEEDLE FREE DRUG DELIVERY MARKET OUTLOOK TO 2020
6.1 Current Market size and Future Outlook
7. MARKET SEGMENTATION
7.1 By Technology
7.1.1 Oral Drug Delivery System
7.1.2 Inhaler Drug Delivery System
7.1.3 Transdermal Drug Delivery System
7.1.4 Jet injector Drug Delivery System
7.1.5 Micro Needle Drug Delivery System
7.2 By Application
7.3 By geography
8. INDUSTRY TRENDS
8.1 Introduction of Low Cost Inhalers for Developing Countries
8.2 Innovation in Advanced Dry Powder Inhalers
8.3 Oral Drug Delivery System goes Electrical
8.4 Consolidation in the Market
9. COMPETITOR PROFILES
9.1 Mylan Inc.
9.2 3M (MMM)
9.3 Novatis
9.4 AstraZeneca Plc
9.5 Antares Pharma, Inc.
9.6 GlaxoSmithKline Plc (GSK)
9.7 Sanofi
9.8 Boehringer Ingelheim GmbH
9.9 Merck & Co.
2. RESEARCH METHODOLOGY
3. DRIVERS
3.1 Increasing Incidence of Chronic Diseases
3.2 Increased Affordability
3.3 Benefits over Conventional Drug Delivery Devices
3.4 Expansion in Emerging Markets
4. CHALLENGES
4.1 High Prices
4.2 Testing and Regulatory Issues
4.3 Low Awareness
5. REGULATORY LANDSCAPE
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
6. NEEDLE FREE DRUG DELIVERY MARKET OUTLOOK TO 2020
6.1 Current Market size and Future Outlook
7. MARKET SEGMENTATION
7.1 By Technology
7.1.1 Oral Drug Delivery System
7.1.2 Inhaler Drug Delivery System
7.1.3 Transdermal Drug Delivery System
7.1.4 Jet injector Drug Delivery System
7.1.5 Micro Needle Drug Delivery System
7.2 By Application
7.3 By geography
8. INDUSTRY TRENDS
8.1 Introduction of Low Cost Inhalers for Developing Countries
8.2 Innovation in Advanced Dry Powder Inhalers
8.3 Oral Drug Delivery System goes Electrical
8.4 Consolidation in the Market
9. COMPETITOR PROFILES
9.1 Mylan Inc.
9.2 3M (MMM)
9.3 Novatis
9.4 AstraZeneca Plc
9.5 Antares Pharma, Inc.
9.6 GlaxoSmithKline Plc (GSK)
9.7 Sanofi
9.8 Boehringer Ingelheim GmbH
9.9 Merck & Co.
LIST OF FIGURES:
Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014
Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014
LIST OF TABLES:
Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
Table 9-2: Mylan - Strengths and Weaknesses
Table 9-3: 3M - Key Financials (Million US$), 2012-2014
Table 9-4: 3M - Strengths and Weaknesses
Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
Table 9-6: Novartis - Strengths and Weaknesses
Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
Table 9-8: Astrazeneca - Strengths and Weaknesses
Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
Table 9-13: Sanofi - Strengths and Weaknesses
Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
Table 9-17: Merck & Co- Strengths and Weaknesses
Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
Table 9-2: Mylan - Strengths and Weaknesses
Table 9-3: 3M - Key Financials (Million US$), 2012-2014
Table 9-4: 3M - Strengths and Weaknesses
Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
Table 9-6: Novartis - Strengths and Weaknesses
Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
Table 9-8: Astrazeneca - Strengths and Weaknesses
Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
Table 9-13: Sanofi - Strengths and Weaknesses
Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
Table 9-17: Merck & Co- Strengths and Weaknesses
